Farah Natoli - Talaris Therapeutics Head Management
| TALSDelisted Stock | USD 2.98 0.10 3.25% |
Insider
Farah Natoli is Head Management of Talaris Therapeutics
| Phone | 502 398 9250 |
| Web | https://talaristx.com |
Talaris Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2281) % which means that it has lost $0.2281 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4164) %, meaning that it created substantial loss on money invested by shareholders. Talaris Therapeutics' management efficiency ratios could be used to measure how well Talaris Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Talaris Therapeutics currently holds 2.88 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Talaris Therapeutics has a current ratio of 28.34, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Talaris Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert Coutts | Achilles Therapeutics PLC | 40 | |
| Mark Dudley | Instil Bio | N/A | |
| Ian Critchley | Spero Therapeutics | N/A | |
| BSc FRCPath | Achilles Therapeutics PLC | 59 | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| DPHIL MD | Vor Biopharma | 51 | |
| Timothy Mayer | NextCure | 59 | |
| Lei Sun | Connect Biopharma Holdings | 60 | |
| Sumita JD | Instil Bio | 50 | |
| Thomas Templeman | Nuvation Bio | 60 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Jamie Moore | CytomX Therapeutics | N/A | |
| Hoyoung MD | CytomX Therapeutics | 55 | |
| Satyavrat CFA | Spero Therapeutics | 51 | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Ted Jenkins | Spero Therapeutics | N/A | |
| Jennifer Michaelson | Cullinan Oncology LLC | 57 | |
| AO FRACP | Assembly Biosciences | 65 | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Jeffrey Rona | Ovid Therapeutics | 56 | |
| Timothy Moore | Instil Bio | 63 | |
Management Performance
| Return On Equity | -0.42 | |||
| Return On Asset | -0.23 |
Talaris Therapeutics Leadership Team
Elected by the shareholders, the Talaris Therapeutics' board of directors comprises two types of representatives: Talaris Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Talaris. The board's role is to monitor Talaris Therapeutics' management team and ensure that shareholders' interests are well served. Talaris Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Talaris Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nancy MD, Chief Officer | ||
| Eric Gornstein, Head Planning | ||
| Suzanne Tollerud, VP Devel | ||
| Michael Zdanowski, Chief Officer | ||
| JD LLB, CEO and President | ||
| Suzanne MD, Member Founder | ||
| Mary Fenton, CFO Treasurer | ||
| Farah Natoli, Head Management | ||
| Colby Suire, Head RD | ||
| Andrew Farnsworth, Chief Officer |
Talaris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Talaris Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.42 | |||
| Return On Asset | -0.23 | |||
| Current Valuation | (28.92 M) | |||
| Shares Outstanding | 42.81 M | |||
| Shares Owned By Insiders | 11.90 % | |||
| Shares Owned By Institutions | 77.67 % | |||
| Number Of Shares Shorted | 340.1 K | |||
| Price To Book | 0.28 X | |||
| EBITDA | (74.31 M) | |||
| Net Income | (73.89 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Talaris Stock
If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |